NEULANDLAB.BONEULANDLAB.BOBSE
Loading
EBITDA Over TimeContracting
Percentile Rank93
3Y CAGR+44.1%
5Y CAGR+33.2%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+44.1%/yr
vs +30.0%/yr prior
5Y CAGR
+33.2%/yr
Recent acceleration
Acceleration
+14.1pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
4.2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$4.20B-11.5%
2024$4.75B+70.1%
2023$2.79B+98.8%
2022$1.40B-13.8%
2021$1.63B+62.3%
2020$1.00B+78.8%
2019$561.12M+14.3%
2018$490.98M-51.4%
2017$1.01B+37.4%
2016$734.91M-